Bradley Pharmaceuticals Inc Watch

from 8-K ~5 pages Plan of reorganization, merger, acquisition or similar

from 8-K ~50 pages Agreement and Plan of Merger

from 8-K ~5 pages First Amendment to Asset Purchase Agreement

from 10-Q ~50 pages Asset Purchase Agreement by and Among Quintiles Transnational Corp., Quintiles Bermuda Ltd., Quintiles Ireland Limited, Bioglan Pharmaceuticals Company, and Bradley Pharmaceuticals, Inc. June 8, 2004

from 8-K ~5 pages Exhibit 10.29 Revolving Promissory Note

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, 2002 2001 Net Sales $ 9,894,754 $ 6,648,439 Cost of Sales 1,032,999 1,208,561 8,861,755 5,439,878 Selling, General and Administrative Expenses 5,376,003 3,661,652 Depreciation and Amortization 285,764 292,551 Interest Income - Net 90,629 19,030 5,571,138 3,935,173 Income Before Income Taxes 3,290,617 1,504,705 Income Tax Expense 1,283,000 569,000 Net Income $ 2,007,617 $ 935,705 ============ ============ Net Income Per Common Share Basic $ 0.19 $ 0.11 ============ ============ Diluted $ 0.18 $ 0.10 ============ ============ Weighted Average Number of Common Shares Basic 10,510,000 8,520,000 ============ ============ Diluted 11,340,000 9,830,000 ============ ============ Nine Months Ended September 30, 2002 2001 Net Sales $ 28,543,737 $ 17,855,114 Cost of Sales 3,230,201 3,135,875 25,313,536 14,719,239 Selling, General and Administrative Expenses 15,641,868 11,031,217 Depreciation and Amortization 841,916 827,301 Interest Income - Net 225,163 7,266 16,258,621 11,851,252 Income Before Income Taxes 9,054,915 2,867,987 Income Tax Expense 3,531,000 1,080,000 Net Income $ 5,523,915 $ 1,787,987 =========== =========== Net Income Per Common Share Basic $ 0.53 $ 0.22 =========== =========== Diluted $ 0.48 $ 0.19 =========== =========== Weighted Average Number of Common Shares Basic 10,460,000 8,150,000 =========== =========== Diluted 11,440,000 9,230,000 =========== =========== See Notes to Condensed Consolidated Financial Statements 4

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2002 2001 2002 2001 Net Sales $ 9,355,657 $ 5,923,566 $ 18,648,983 $ 11,206,675 Cost of Sales 1,086,658 939,660 2,197,202 1,927,314 8,268,999 4,983,906 16,451,781 9,279,361 Selling, General and Administrative Expenses 5,106,127 3,834,926 10,265,865 7,369,565 Depreciation and Amortization 281,930 290,536 556,152 534,750 Interest Expense (Income) - Net (57,512) (28,223) (134,534) 11,764 5,330,545 4,097,239 10,687,483 7,916,079 Income Before Income Taxes 2,938,454 886,667 5,764,298 1,363,282 Income Tax Expense 1,146,000 339,000 2,248,000 511,000 Net Income $ 1,792,454 $ 547,667 $ 3,516,298 $ 852,282 ============ =========== =========== =========== Net Income Per Common Share Basic $ 0.17 $ 0.07 $ 0.34 $ 0.11 ============ =========== =========== =========== Diluted $ 0.16 $ 0.06 $ 0.31 $ 0.10 ============ =========== =========== =========== Weighted Average Number of Common Shares Basic 10,460,000 7,970,000 10,440,000 7,960,000 ============ =========== =========== =========== Diluted 11,430,000 9,280,000 11,500,000 8,930,000 ============ =========== =========== =========== See Notes to Condensed Consolidated Financial Statements 4

from DEF 14A 1 page Proxy Card Common

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, 2002 2001 Net Sales $ 9,293,326 $ 5,283,109 Cost of Sales 1,110,544 987,654 8,182,782 4,295,455 Selling, General and Administrative Expenses 5,159,738 3,534,639 Depreciation and Amortization 274,222 244,214 Interest Expense (Income) - Net (77,022) 39,987 5,356,938 3,818,840 Income Before Income Taxes 2,825,844 476,615 Income Tax Expense 1,102,000 172,000 Net Income $ 1,723,844 $ 304,615 =========== =========== Net Income Per Common Share Basic $ 0.17 $ 0.04 =========== =========== Diluted $ 0.15 $ 0.04 =========== =========== Weighted Average Number of Common Shares Basic 10,430,000 7,970,000 =========== =========== Diluted 11,570,000 8,600,000 =========== =========== See Notes to Condensed Consolidated Financial Statements 4

from 10KSB 1 page Plan of reorganization, merger, acquisition or similar

from 10QSB/A 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2001 2000 2001 2000 Net Sales $ 6,648,439 $ 4,667,772 $ 17,855,114 $ 11,556,819 Cost of Sales 1,208,561 1,060,740 3,135,875 2,915,107 5,439,878 3,607,032 14,719,239 8,641,712 Selling, General and Administrative Expenses 3,661,652 2,695,508 11,031,217 8,103,652 Depreciation and Amortization 292,551 225,521 827,301 707,598 Interest Expense (Income) - Net (19,030) 70,229 (7,266) 182,167 Loss Due to Impairment of Asset - - - 3,897,000 3,935,173 2,991,258 11,851,252 12,890,417 Income (Loss) Before Income Taxes 1,504,705 615,774 2,867,987 (4,248,705) Income Tax Expense (Benefit) 569,000 240,000 1,080,000 (137,000) Net Income (Loss) $ 935,705 $ 375,774 $ 1,787,987 $ (4,111,705) ========== ========== =========== =========== Net Income (Loss) Per Common Share Basic $ 0.11 $ 0.05 $ 0.22 $ (0.52) ========== ========== =========== =========== Diluted $ 0.10 $ 0.05 $ 0.19 $ (0.52) ========== ========== =========== =========== Weighted Average Number of Common Shares Basic 8,520,000 7,910,000 8,150,000 7,900,000 ========== ========== =========== =========== Diluted 9,830,000 7,960,000 9,230,000 7,900,000 ========== ========== =========== =========== See Notes to Condensed Consolidated Financial Statements 5

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2001 2000 2001 2000 Net Sales $ 6,648,439 $ 4,667,772 $ 17,855,114 $ 11,556,819 Cost of Sales 1,208,561 1,060,740 3,135,875 2,915,107 5,439,878 3,607,032 14,719,239 8,641,712 Selling, General and Administrative Expenses 3,661,652 2,695,508 11,031,217 8,103,652 Depreciation and Amortization 292,551 225,521 827,301 707,598 Interest Expense (Income) - Net (19,030) 70,229 (7,266) 182,167 Loss Due to Impairment of Asset - - - 3,897,000 3,935,173 2,991,258 11,851,252 12,890,417 Income (Loss) Before Income Taxes 1,504,705 615,774 2,867,987 (4,248,705) Income Tax Expense (Benefit) 569,000 240,000 1,080,000 (137,000) Net Income (Loss) $ 935,705 $ 375,774 $ 1,787,987 $ (4,111,705) ========== ========== =========== =========== Net Income (Loss) Per Common Share Basic $ 0.11 $ 0.05 $ 0.22 $ (0.52) ========== ========== =========== =========== Diluted $ 0.10 $ 0.05 $ 0.19 $ (0.52) ========== ========== =========== =========== Weighted Average Number of Common Shares Basic 8,520,000 7,910,000 8,150,000 7,900,000 ========== ========== =========== =========== Diluted 9,830,000 7,960,000 9,230,000 7,900,000 ========== ========== =========== =========== See Notes to Condensed Consolidated Financial Statements 4

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2001 2000 2001 2000 Net Sales $ 5,923,566 $ 4,091,755 $ 11,206,675 $ 6,889,047 Cost of Sales 939,660 976,402 1,927,314 1,854,367 4,983,906 3,115,353 9,279,361 5,034,680 Selling, General and Administrative Expenses 3,834,926 2,508,007 7,369,565 5,408,144 Depreciation and Amortization 290,536 237,445 534,750 482,077 Interest Expense (Income) - Net (28,223) 54,491 11,764 111,938 Loss Due to Impairment of Asset - - - 3,897,000 4,097,239 2,799,943 7,916,079 9,899,159 Income (Loss) Before Income Taxes 886,667 315,410 1,363,282 (4,864,479) Income Tax Expense (Benefit) 339,000 123,000 511,000 (377,000) Net Income (Loss) $ 547,667 $ 192,410 $ 852,282 $ (4,487,479) ========== ========== ========== ========== Net Income (Loss) Per Common Share Basic $ 0.07 $ 0.02 $ 0.11 $ (0.57) ========== ========== ========== ========== Diluted $ 0.06 $ 0.02 $ 0.10 $ (0.57) ========== ========== ========== ========== Weighted Average Number of Common Shares Basic 7,970,000 7,910,000 7,960,000 7,900,000 ========== ========== ========== ========== Diluted 9,280,000 8,020,000 8,930,000 7,900,000 ========== ========== ========== ========== See Notes to Condensed Consolidated Financial Statements

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet March 31, 2001 (Unaudited) Assets Current Assets - Cash and Cash Equivalents $ 139,952 Short-Term Investments 2,000,000 Accounts Receivable - Net 3,747,047 Finished Goods Inventory 1,533,162 Deferred Tax Asset 339,459 Prepaid Samples and Materials 502,859 Prepaid Expenses and Other 129,402 Total Current Assets 8,391,881 Property and Equipment - Net 599,039 Intangibles - Net 7,898,547 Deferred Tax Asset 678,200 Other Assets 82,961 Total Assets $ 17,650,628 ============ Liabilities and Stockholders' Equity Current Liabilities - Current Maturities of Long-Term Debt $ 532,740 Revolving Credit Line 1,280,748 Accounts Payable 1,475,900 Accrued Expenses 1,138,036 Income Taxes Payable 127,753 Total Current Liabilities 4,555,177 Long-Term Debt, Less Current Maturities 795,117 Stockholders' Equity - Preferred Stock, $.01 Par Value; Authorized, 2,000,000 Shares; Issued, None - Common Stock, $.01 Par Value, Authorized 26,400,000; Issued 8,260,165 Shares at March 31, 2001 14,835,177 Common, Class B, $.01 Par Value, Authorized 900,000 Shares, Issued and Outstanding, 431,552 Shares at March 31, 2001 845,448 Treasury Stock, at Cost (720,939 Shares at March 31, 2001) (1,007,527) Accumulated Deficit (2,372,764) 12,300,334 Total Liabilities & Stockholders' Equity $ 17,650,628 =========== See Notes to Condensed Consolidated Financial Statements

from 10KSB 1 page Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Balance Sheets December 31, Assets 2000 1999 Current Assets Cash and Cash Equivalents $ 453,200 $ 385,640 Accounts Receivable - Net of Allowances 5,370,650 4,471,333 Inventory 1,598,387 2,181,754 Deferred Tax Asset 344,186 - Prepaid Samples and Materials 354,283 635,507 Prepaid Expenses and Other 48,678 65,742 Total Current Assets 8,169,384 7,739,976 Property and Equipment, Net 254,781 298,244 Intangible Assets, Net 8,105,429 12,841,501 Deferred Tax Asset 699,101 - Other Assets 91,841 167,921 $ 17,320,536 $ 21,047,645 ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-3 Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Balance Sheets December 31, Liabilities and Shareholders' Equity 2000 1999 Current Liabilities Current Maturities of Long-Term Debt $ 464,643 $ 1,228,674 Revolving Credit Line 577,639 2,120,321 Accounts Payable 1,754,854 2,032,026 Accrued Expenses 1,812,124 1,382,634 Income Taxes Payable 148,227 238,998 Total Current Liabilities 4,757,487 7,002,653 Long-Term Debt, Less Current Maturities 661,569 162,922 Commitments and Contingencies Shareholders' Equity Preferred Stock, $.01 Par Value; Authorized, 2,000,000 Shares; Issued - None - - Common Stock, $.01 Par Value, Authorized, 26,400,000 Shares; Issued 8,206,627 in 2000, 8,199,683 Shares in 1999 14,778,631 14,759,011 Common, Class B, $.01 Par Value, Authorized, 900,000 Shares; Issued and Outstanding, 431,552 Shares in 2000 and 1999 845,448 845,448 Treasury Stock - Common Stock - At Cost (740,481 Shares in 2000 and 766,425 in 1999) (1,045,220) (1,107,842) Accumulated Deficit (2,677,379) (614,547) 11,901,480 13,882,070 $ 17,320,536 $ 21,047,645 ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-4

from 4 1 page Plan of reorganization, merger, acquisition or similar

from 10KSB 1 page Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Balance Sheets December 31, Assets 1999 1998 Current Assets Cash and Cash Equivalents $ 385,640 $ 1,417,746 Accounts Receivable - Net of Allowance for Doubtful Accounts of $267,000 in 1999, $411,000 in 1998 5,947,266 4,215,303 Inventory 2,181,754 1,506,731 Prepaid Samples and Materials 635,507 1,144,912 Prepaid Expenses and Other 65,742 33,252 Total Current Assets 9,215,909 8,317,944 Property and Equipment, Net 298,244 357,010 Intangible Assets, Net 12,841,504 13,778,878 Other Assets 167,921 110,429 $ 22,523,578 $ 22,564,261 ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-3 Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Balance Sheets December 31, Liabilities and Shareholders' Equity 1999 1998 Current Liabilities Current Maturities of Long-Term Debt $ 1,228,674 $ 170,531 Revolving Credit Line 2,120,321 2,395,703 Accounts Payable 2,032,026 1,842,297 Accrued Expenses 2,858,567 2,953,944 Income Taxes Payable 238,998 84,532 Total Current Liabilities 8,478,586 7,447,007 Long-Term Debt, Less Current Maturities 162,922 1,245,851 Commitments and Contingencies Shareholders' Equity Preferred Stock, $.01 Par Value; Authorized, 2,000,000 Shares; Issued - None - - Common Stock, $.01 Par Value, Authorized, 26,400,000 Shares; Issued 8,199,683 in 1999, 8,189,315 Shares in 1998 14,759,011 14,761,947 Common, Class B, $.01 Par Value, Authorized, 900,000 Shares; Issued and Outstanding, 431,552 Shares in 1999 and 1998 845,448 845,448 Treasury Stock - Common Stock - At Cost (766,425 Shares in 1999 and 373,933 in 1998) (1,107,842) (560,883) Accumulated Deficit (614,547) (1,175,109) 13,882,070 13,871,403 $ 22,523,578 $ 22,564,261 ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-4

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 1999 1998 1999 1998 Net Sales $ 4,128,173 $ 2,463,228 $ 13,544,105 $ 10,392,630 Cost of Sales 1,070,773 882,061 3,725,770 3,216,464 3,057,400 1,581,167 9,818,335 7,176,166 Selling, General and Administrative Expenses 2,880,761 2,023,555 7,851,404 6,072,006 Depreciation and Amortization 257,305 265,612 896,355 803,759 Interest Expense - Net 51,014 31,187 173,088 114,857 3,189,080 2,320,354 8,920,847 6,990,622 Income (Loss) Before Income Taxes (131,680) (739,187) 897,488 185,544 Income Tax Provision (Benefit) (48,000) (274,000) 332,000 68,000 Net Income (Loss) $ (83,680) $ (465,187) $ 565,488 $ 117,544 ========== ============ =========== ============ Net Income (Loss) Per Common Share Basic & Diluted $ (0.01) $ (0.06) $ 0.07 $ 0.01 ========== ============ =========== ============ Weighted Average Number of Common Shares Basic 7,900,000 8,420,000 8,010,000 8,430,000 =========== =========== =========== ============ Diluted 7,930,000 8,420,000 8,070,000 9,160,000 =========== =========== =========== ============ See Notes to Condensed Consolidated Financial Statements 4

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 1999 1998 1999 1998 Net Sales $ 4,287,462 $ 3,688,121 $ 9,415,932 $ 7,929,402 Cost of Sales 1,345,770 1,019,606 2,654,997 2,334,403 2,941,692 2,668,515 6,760,935 5,594,999 Selling, General and Administrative Expenses 2,432,459 2,078,124 4,970,643 4,048,451 Depreciation and Amortization 316,044 264,713 639,050 538,147 Interest Expense - Net 47,346 41,503 122,074 83,670 2,795,849 2,384,340 5,731,767 4,670,268 Income Before Income Taxes 145,843 284,175 1,029,168 924,731 Income Taxes 53,000 105,000 380,000 342,000 Net Income $ 92,843 $ 179,175 $ 649,168 $ 582,731 ========== ========== ========== ========== Net Income Per Common Share Basic $ 0.01 $ 0.02 $ 0.08 $ 0.07 ========== ========== ========== ========== Diluted $ 0.01 $ 0.02 $ 0.08 $ 0.06 ========== ========== ========== ========== Weighted Average Number of Common Shares Basic 7,970,000 8,420,000 8,050,000 8,440,000 ========== ========== ========== ========== Diluted 8,070,000 9,420,000 8,130,000 9,350,000 ========== ========== ========== ========== See Notes to Condensed Consolidated Financial Statements 4

from 10QSB 1 page Plan of reorganization, merger, acquisition or similar